Navigation Links
BioPharm Insight Releases its Catalyst Monitor for April 2013
Date:3/26/2013

Norwood, MA (PRWEB) March 26, 2013

BioPharm Insight’s monthly Catalyst Monitor analyzes the most material events in the sector during the upcoming month. The Catalyst Monitor tracks significant events and announcements such as US Food and Drug Administration (FDA) approvals, Advisory Committee meetings and expected key clinical results.

Allergan’s Levadex (dihydroergotamine mesylate) is expected to receive FDA approval for the treatment of acute migraines. Its review date is 15 April. The Phase III FREEDOM-301 study impressively hit its four co-primary endpoints and had an excellent safety and tolerability profile. Additionally, Levadex’s pain relief scores are similar to what is seen from marketed triptans. A human factors study cannot be ruled out, though, considering the FDA has previously delayed applications for migraine products, notably GlaxoSmithKline and Pozen’s Treximet (sumatriptan naproxen sodium).

Despite a three month delay by the FDA for an approval decision date, Sucampo Pharmaceuticals and Takeda Pharmaceutical Company’s Amitiza (lubiprostone) is anticipated to get the green light for opioid-induced constipation. Experts noted that the Phase III open-label study results indicated the drug is safe and efficacious. Approval in two indica¬tions, chronic idiopathic constipation and irritable bowel syndrome with constipation, further underscores the drug’s solid safety profile.

On the development front, Trius Therapeutics and Bayer’s second Phase III TR-701 (tedizolid phosphate) trial is expected to have positive results. But anti-infectives experts questioned, however, the validity of Trius’ claims of greater potency and lesser toxicity as tedizolid’s benefits over Pfizer’s Zyvox (linezolid) based on current evidence.

Other catalysts in April include:

  •     Raptor Pharmaceutical’s cystinosis candidate, RP103, expected to clinch FDA nod
  •     Titan Pharmaceuticals’ opioid-dependence drug, Probuphine, will likely get FDA go-ahead, but market size is questionable
  •     XenoPort’s arbaclofen for multiple sclerosis spasticity is expected to yield Phase III efficacy

Learn how BioPharm Insight can help you find new business opportunities by starting a free trial today.

About BioPharm Insight
BioPharm Insight is the definitive guide to the global biopharma community. BioPharm Insight provides subscribers with an information edge by combining the most comprehensive real-time database of companies, drugs, contacts, M&A and licensing deals, forecasts and clinical trial data with proprietary forward-looking intelligence uncovered by an independent team of investigative journalists months or even years before it breaks in mainstream media. To learn more, visit http://www.biopharminsight.com. Follow BioPharm Insight on LinkedIn and Twitter.

About Infinata, Inc.
Infinata provides personalized technology solutions to turn information into insight. Services include a comprehensive BioPharm Solutions Suite, unique Wealth Prospecting tools and innovative Custom Data Services. Infinata is a part of Mergermarket, a Financial Times Group company and a division of Pearson plc. To learn more, visit http://www.infinata.com.

Read the full story at http://www.prweb.com/releases/2013/3/prweb10562274.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
2. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
3. Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference
4. Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
5. ISPE Conference to Benchmark and Advance Quality by Design in the Biopharmaceutical Industry
6. Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
7. Array Biopharma and Global Blood Therapeutics Announce Drug Discovery Collaboration Focused on Hematology
8. Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
9. Infinata's BioPharm Insight Journalist Awarded Fellowship by Association of Health Care Journalists
10. PDL BioPharma to Present at Two Upcoming Investor Conferences
11. Patheon Exhibits at the 2013 Biopharmaceutical Development and Production Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Baltimore bio tech firm, ... security screening solution at the National Postal Forum 2017 in Baltimore, Maryland, May ... highly accurate, easy to use and low cost threat detection solution for government ...
(Date:4/25/2017)... California (PRWEB) , ... April 25, 2017 , ... ... Intelligence (AI), leading supplier of Common Lisp (CL) development tools, and market leader ... , which includes key performance enhancements now available within the most effective system ...
(Date:4/25/2017)... WA (PRWEB) , ... April 25, 2017 , ... Leaders ... division of Quorum, will be featured in multiple sessions at this week’s Association ... from emerging trends to best practices in clinical research. , "We are excited to ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... and Webster Bank, today announced first round funding to three startups through the ... early-stage financial support to new business startups affiliated with UConn. , The UConn ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong ... identification by adopting ground breaking 3D fingerprint minutiae recovery and matching ... and accuracy for use in identification, crime investigation, immigration control, security ... ... A research team led by ...
(Date:3/27/2017)... N.Y. , March 27, 2017  Catholic ... Information and Management Systems Society (HIMSS) Analytics for ... EMR Adoption Model sm . In addition, CHS ... of U.S. hospitals using an electronic medical record ... for its high level of EMR usage in ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Biology News(10 mins):